Clinical trial
A Phase II Study to Evaluate the Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
NCT03594045 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Evaluate the Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 18, 2018
- Completion date
- October 30, 2019
- Enrollment
- 5 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
heparin-induced thrombocytopenia, heparin-induced thrombocytopenia and thrombosis